Theravance Biopharma, Inc. (NASDAQ:TBPH)‘s stock had its “sell” rating reiterated by investment analysts at Robert W. Baird in a note issued to investors on Wednesday. They currently have a $22.00 price objective on the biopharmaceutical company’s stock. Robert W. Baird’s target price would suggest a potential downside of 23.77% from the company’s current price.

Other research analysts have also recently issued reports about the stock. Cantor Fitzgerald set a $55.00 price objective on shares of Theravance Biopharma and gave the stock a “buy” rating in a research report on Wednesday, August 16th. Needham & Company LLC restated a “buy” rating on shares of Theravance Biopharma in a research report on Wednesday, August 2nd. Zacks Investment Research upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Tuesday, September 19th. ValuEngine upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Wednesday, September 13th. Finally, BidaskClub cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. Four research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $41.86.

Shares of Theravance Biopharma (NASDAQ:TBPH) opened at 28.86 on Wednesday. The firm’s market capitalization is $1.55 billion. Theravance Biopharma has a 1-year low of $23.15 and a 1-year high of $43.44. The stock has a 50 day moving average of $32.83 and a 200-day moving average of $35.05.

ILLEGAL ACTIVITY WARNING: This article was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://theolympiareport.com/2017/11/01/theravance-biopharma-inc-tbph-receives-sell-rating-from-robert-w-baird.html.

In other news, Director Henrietta Fore bought 6,000 shares of the business’s stock in a transaction on Friday, August 11th. The stock was acquired at an average price of $23.99 per share, with a total value of $143,940.00. Following the completion of the purchase, the director now directly owns 24,000 shares in the company, valued at $575,760. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Rick E. Winningham bought 10,000 shares of the business’s stock in a transaction on Friday, August 11th. The stock was purchased at an average cost of $24.50 per share, with a total value of $245,000.00. Following the purchase, the chief executive officer now owns 866,377 shares of the company’s stock, valued at $21,226,236.50. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 20,000 shares of company stock valued at $494,300. 6.10% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of TBPH. Parametric Portfolio Associates LLC boosted its stake in Theravance Biopharma by 3.3% in the first quarter. Parametric Portfolio Associates LLC now owns 14,090 shares of the biopharmaceutical company’s stock worth $519,000 after buying an additional 456 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in Theravance Biopharma in the first quarter worth approximately $420,000. Teachers Advisors LLC boosted its stake in Theravance Biopharma by 15.2% in the first quarter. Teachers Advisors LLC now owns 80,113 shares of the biopharmaceutical company’s stock worth $2,950,000 after buying an additional 10,550 shares in the last quarter. Legal & General Group Plc boosted its stake in Theravance Biopharma by 11.6% in the first quarter. Legal & General Group Plc now owns 15,713 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 1,631 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Theravance Biopharma by 4.2% in the first quarter. Vanguard Group Inc. now owns 3,080,296 shares of the biopharmaceutical company’s stock worth $113,417,000 after buying an additional 125,223 shares in the last quarter. 84.86% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Analyst Recommendations for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.